Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 65, Issue 2, Pages 218-223Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jac/dkp447
Keywords
HIV; integrase inhibitors; antiretroviral therapy
Funding
- Fundacion Investigacion y Educacion en SIDA (IES)
- European NEAT project
- Red de Investigacion en SIDA (RIS)
- Fondo de Investigacion Sanitaria-FIS [CP06/0284, PI06/1826]
- [RD06/006]
Ask authors/readers for more resources
Raltegravir (Isentress((R))) is the first approved HIV integrase inhibitor. Agents in this class target a different viral enzyme compared with agents inhibiting reverse transcriptase and protease. A wide number of patients are currently susceptible to integrase inhibitors, including heavily antiretroviral-experienced patients harbouring drug-resistant viruses. The good tolerability and convenience of raltegravir have recently begun to be appreciated, leading to the consideration of other indications for the drug. Data recently released using the drug as first-line therapy or in switch strategies are very promising and the role of raltegravir in intensification therapy is currently under investigation. Altogether, the current information supports a broad use of raltegravir beyond its initial approval for antiretroviral-experienced HIV-infected patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available